# Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial

> **NCT06919380** · PHASE1 · RECRUITING · sponsor: **Li Shiyue** · enrollment: 10 (estimated)

## Conditions studied

- Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD
- Rapidly Progressive Interstitial Lung Disease

## Interventions

- **DRUG:** MSC-exos Nebulization Therapy

## Key facts

- **NCT ID:** NCT06919380
- **Lead sponsor:** Li Shiyue
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919380, "Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06919380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*